Open-label study with a single treatment arm of the multicentre, randomized, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of o, 5 mg FTY720 administered orally once a day versus placebo in patients with progressive primary multiple sclerosis
Pathology and candidate patients
Dr. Luís Martí Bonmatí
Hospital Quirónsalud Valencia.
April 30, 2013
Hospital La Fe
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the image diagnosis team by sending an email to the address: firstname.lastname@example.org